InMode Ltd.

NASDAQ (USD): InMode Ltd. (INMD)

Last Price

16.50

Today's Change

+0.34 (2.10%)

Day's Change

16.059 - 16.84

Trading Volume

1,389,129

Overview

Market Cap

1 Billion

Shares Outstanding

84 Million

Avg Volume

1,191,440

Avg Price (50 Days)

16.25

Avg Price (200 Days)

19.08

PE Ratio

9.54

EPS

1.73

Earnings Announcement

30-Oct-2024

Previous Close

16.16

Open

16.12

Day's Range

16.06 - 16.84

Year Range

14.87 - 26.8

Trading Volume

1,402,634

Price Change Highlight

1 Day Change

2.10%

5 Day Change

5.23%

1 Month Change

-3.17%

3 Month Change

-7.67%

6 Month Change

-7.92%

Ytd Change

-25.74%

1 Year Change

-20.48%

3 Year Change

-80.78%

5 Year Change

21.41%

10 Year Change

143.00%

Max Change

143.00%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Medical Devices

Description:

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment